Prices are updated after-hours

Manufacturing Biological product (except diagnostic) manufacturing

ImmunityBio Inc

IBRX | $5.265 7.23% 6.74% 4.6M

|

(0.0% 1d) (-14.6% 1m) (96.6% 1y) (7.3% 2d) (0.6% 3d) (0.6% 7d) (30.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 3,564,422,959
https://immunitybio.com
Sec Filling | Patents | n/a employees

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.

cancer t-cell infectious disease immunotherapy ceiling injection optical

add to watch list Paper trade email alert is off

Palisade Bio Inc

PALI | $4.735 -6.61% -7.07% 140K

|

(0.0% 1d) (1108.3% 1m) (167.6% 1y) (0.0% 2d) (-28.6% 3d) (14.7% 7d) (-90.71% volume)
Earnings Calendar: 2022-11-11
Market Cap: $ 60,470,756
https://www.palisadebio.com
Sec Filling | Patents | n/a employees

(US) Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

education msa gastrointestinal

add to watch list Paper trade email alert is off

SolarWindow Technologies, Inc.

WNDW | $0.31 61.29% 6.6K

|

(0.0% 1d) (3.1% 1m) (22.2% 1y) (0.0% 2d) (0.0% 3d) (4.7% 7d) (-33.66% volume)
Earnings Calendar:
Market Cap: $ 16,491,504
https://solarwindow.com/
Sec Filling | Patents | 7 employees

(United States) solarwindow™ technologies, inc. (otcqb: solw) is developing first-of-their-kind electricity-generating see-through windows and products for america’s 85 million detached homes and commercial buildings. our mission has been to create solarwindow™ products which produce extraordinary amounts of clean electricity, financially reward our customers, and benefit the environment.

eletrical

add to watch list Paper trade email alert is off

MYMETICS CORP

MYMX 4 | $0.0016 0.0% 4.8M

|

(0.0% 1d) (0.0% 1m) (-77.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1988.71% volume)
Earnings Calendar:
Market Cap: $ 486,012

Sec Filling | Patents | 8 employees

mymetics corporation (otcqb: mymx) is a swiss based biotechnology company, with a research lab in the netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. it has currently has 5 vaccines in its pipeline: hiv-1/aids, intra-nasal influenza, malaria, herpes simplex virus and the rsv vaccine. mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. the company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. the company’s unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including astellas pharma, path-mvi and the bill an

injection influenza pathogens vaccine

add to watch list Paper trade email alert is off

Qrons Inc.

QRON | $0.213 0% 3.2K

|

(0.0% 1d) (0.0% 1m) (-55.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (425.67% volume)
Earnings Calendar:
Market Cap: $ 2,907,405

Sec Filling | Patents | 2 employees

qrons inc., a preclinical stage biotechnology company, engages in developing stem cell synthetic hydrogel-based solutions to combat neuronal injuries, primarily focusing on traumatic brain injuries. its products candidates include qs100, an injury specific, 3d printable, implantable modified mesenchymal stem cells (mscs)-synthetic hydrogel to treat penetrating brain injuries; and qs200, an injectable mscs-synthetic hydrogel for the treatment of diffused injuries. qrons inc. has a license and research funding agreement with ariel university r&d co., ltd. for the development and commercialization of products for neuronal tissue regeneration and repair. the company was formerly known as biolabmart inc. and changed its name to qrons inc. in august 2017. qrons inc. was founded in 2016 and is based in new york, new york.

injection t-cell

add to watch list Paper trade email alert is off

Oncotelic Therapeutics, Inc.

OTLC | $0.042 -44.63% 100K

|

(0.0% 1d) (7.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-2.7% 7d) (-42.74% volume)
Earnings Calendar:
Market Cap: $ 16,743,911

Sec Filling | Patents | 15 employees

add to watch list Paper trade email alert is off

ENZON PHARMACEUTICALS, INC.

ENZN | $0.0724 136.11% 540

|

(0.0% 1d) (-19.0% 1m) (-69.0% 1y) (0.0% 2d) (0.0% 3d) (-13.4% 7d) (-99.54% volume)
Earnings Calendar:
Market Cap: $ 5,373,137
http://enzon.com/
Sec Filling | Patents | n/a employees

(US) enzon pharmaceuticals, inc., together with its subsidiaries, engages in licensing drug products. its marketed drug products include pegintron and sylatron. the company was founded in 1981 and is headquartered in cranford, new jersey.

add to watch list Paper trade email alert is off

PharmaCyte Biotech Inc

PMCB | $2.2 0.0% 11K

|

(0.0% 1d) (-12.0% 1m) (-28.9% 1y) (0.0% 2d) (0.0% 3d) (0.5% 7d) (20.64% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 18,597,471
https://www.pharmacytebiotech.com
Sec Filling | Patents | 4 employees

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.

diabetic diabetes msa ceiling cancer genetic t-cell

add to watch list Paper trade email alert is off

Humacyte Inc

HUMA | $3.7 3.06% 2.97% 4.9M

|

(0.0% 1d) (2.8% 1m) (11.8% 1y) (3.1% 2d) (18.6% 3d) (28.9% 7d) (-15.47% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 440,609,794
https://humacyte.com
Sec Filling | Patents | n/a employees

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

diabetic diabetes ceiling treatment defense t-cell

add to watch list Paper trade email alert is off

CYTRX CORP

CYTR | $0.092

|

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-91.73% volume)
Earnings Calendar:
Market Cap: $ 4,143,440
http://www.cytrx.com/
Sec Filling | Patents | 4 employees

(US)

add to watch list Paper trade email alert is off

PREMIER BIOMEDICAL INC

BIEI | $0.0012 -23.08% 410K

|

(0.0% 1d) (22.2% 1m) (-8.3% 1y) (0.0% 2d) (0.0% 3d) (-8.3% 7d) (21484.44% volume)
Earnings Calendar:
Market Cap: $ 1,318,655
https://www.premierbiomedical.com/
Sec Filling | Patents | n/a employees

(United States) premier biomedical llc is a biotechnology company located in 6102 indian mound dr, mc farland, wisconsin, united states.

add to watch list Paper trade email alert is off

Point of Care Nano-Technology, Inc.

PCNT | $0.0025 0% 580

|

(0.0% 1d) (0.0% 1m) (316.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (475.0% volume)
Earnings Calendar:
Market Cap: $ 1,052

Sec Filling | Patents | 1 employees

add to watch list Paper trade email alert is off

Green Planet Bio Engineering Co. Ltd.

GPLB | $1.0 -90.91% 100

|

(0.0% 1d) (0.0% 1m) (-9.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-80.0% volume)
Earnings Calendar:
Market Cap: $ 20,006,402

Sec Filling | Patents | 1 employees

add to watch list Paper trade email alert is off

Teligent, Inc.

TLGTQ | $0.0002

|

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (11.06% volume)
Earnings Calendar:
Market Cap: $ 18,563
https://www.teligent.com
Sec Filling | Patents | 2357 employees

(US) Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.

add to watch list Paper trade email alert is off

Achilles Therapeutics Plc - ADR

ACHL | $0.7827 -2.16% -2.21% 200K

|

(0.0% 1d) (-38.6% 1m) (-10.3% 1y) (0.0% 2d) (0.0% 3d) (-5.2% 7d) (55.56% volume)
Earnings Calendar:
Market Cap: $ 31,213,392
https://www.achillestx.com
Sec Filling | Patents | n/a employees

(United Kingdom) Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

ceiling cancer lung cancer lungs t-cell

add to watch list Paper trade email alert is off

Evaxion Biotech A/S - ADR

EVAX | $4.2 -0.47% -0.48% 31K

|

(0.0% 1d) (41.3% 1m) (191.2% 1y) (2.1% 2d) (5.6% 3d) (5.1% 7d) (-12.53% volume)
Earnings Calendar:
Market Cap: $ 21,903,231
https://www.evaxion-biotech.com
Sec Filling | Patents | 2020 employees

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.

vaccine cancer immunotherapy infectious disease injection batteries skin

add to watch list Paper trade email alert is off

Immunocore Holdings plc - ADR

IMCR | $55.71 1.77% 1.74% 450K

|

(0.0% 1d) (-10.0% 1m) (-9.6% 1y) (1.7% 2d) (2.0% 3d) (0.3% 7d) (3.11% volume)
Earnings Calendar:
Market Cap: $ 2,775,506,350
https://www.immunocore.com
Sec Filling | Patents | 2020 employees

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

urea cancer immunotherapy infectious disease

add to watch list Paper trade email alert is off

Valneva SE - ADR

VALN | $7.96 -2.09% -2.13% 8.5K

|

(0.0% 1d) (2.3% 1m) (-29.8% 1y) (-6.8% 2d) (-2.2% 3d) (-10.8% 7d) (208.01% volume)
Earnings Calendar:
Market Cap: $ 552,870,325
https://valneva.com/
Sec Filling | Patents | 2021 employees

(FR) Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.

vaccine ixchiq chikungunya

add to watch list Paper trade email alert is off

GENETHERA INC

GTHR | $0.006 595.0% 28K

|

(0.0% 1d) (0.0% 1m) (-1.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (27610.0% volume)
Earnings Calendar:
Market Cap: $ 212,000

Sec Filling | Patents | 2 employees

genethera inc is a biotechnology company located in 953 gray fox dr, evergreen, colorado, united states.

add to watch list Paper trade email alert is off

CANNABIS GLOBAL, INC.

CBGL | $0.0001 0.0% 100M

|

(0.0% 1d) (-99.0% 1m) (-99.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (180.91% volume)
Earnings Calendar:
Market Cap: $ 339,347

Sec Filling | Patents | 1 employees

cannabis global, inc., a research and development company, manufactures cannabis, hemp, and related products. the company offers hemp infused foods and beverages, including alcohol-free cocktail mixers, hemp infused coffee products, natural hemp infused candy products, hemp infused fermented tea products, and natural and artificial sweeteners under the hemp you can feel name, as well as coffee pod and single serving beverage pod infusion systems and tetrahydrocannabivarin beverages. it also invests in and provides managerial services in specialized areas of the regulated hemp and cannabis industries. the company was formerly known as mctc holdings, inc. and changed its name to cannabis global, inc. in december 2019. cannabis global, inc. was founded in 2005 and is headquartered in los angeles, california.

add to watch list Paper trade email alert is off

← Previous
1
2
Next →

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

67%

33%

Top 10 Gainers

Last 48 Hours Insiders Buying

RXO P 200000 | $19.37 2.32% 0.0% 1M

|

| 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M

|

| 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K

|

Health Technology

| 22:30
BCDA P 2750 | $0.377 -1.4% 97K

|

Health Technology

| 22:00
RMCF | $3.67 3.38% 3.27% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar